Multiple Myeloma Treatment
多发性骨髓瘤治疗
Duration
6-12 months initial treatment, maintenance ongoing
Recovery
3-4 weeks after transplant, ongoing during maintenance therapy
Savings
~83% vs US
Average savings compared to US prices
Multiple myeloma treatment in China utilizes modern induction regimens (VRd — bortezomib, lenalidomide, dexamethasone) followed by autologous stem cell transplant for eligible patients, with maintenance therapy. Chinese hematology centers offer access to novel agents including daratumumab, carfilzomib, and domestically-developed proteasome inhibitors at substantially lower costs. CAR-T cell therapy targeting BCMA is also available at select centers for relapsed/refractory disease.
Diagnosis & Risk Stratification
Bone marrow biopsy, cytogenetics/FISH, serum free light chains, and imaging (PET-CT or whole-body MRI)
Duration: 1-2 weeksInduction Chemotherapy
4-6 cycles of VRd or similar triplet regimen to achieve deep response
Duration: 4-6 monthsAutologous Stem Cell Transplant
Stem cell collection, high-dose melphalan conditioning, and stem cell infusion
Duration: 3-4 weeksMaintenance Therapy
Lenalidomide maintenance until progression; high-risk patients may add proteasome inhibitor
Duration: Ongoing 2+ years- Access to novel agents and CAR-T at fraction of Western costs
- Experienced transplant centers with high-volume programs
- Domestically-produced targeted drugs improve affordability
- Comprehensive supportive care including bone protection
- Transplant-related morbidity including infections
- Treatment is not curative — relapse is expected
- Peripheral neuropathy from proteasome inhibitors
- Secondary malignancies with long-term lenalidomide use
Prices shown are approximate ranges for reference only. Actual costs vary by hospital, complexity, and individual patient needs. Always consult with healthcare professionals for medical decisions.